Clayton A. Smith

9.8k total citations · 2 hit papers
129 papers, 5.5k citations indexed

About

Clayton A. Smith is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Clayton A. Smith has authored 129 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hematology, 45 papers in Molecular Biology and 31 papers in Genetics. Recurrent topics in Clayton A. Smith's work include Acute Myeloid Leukemia Research (42 papers), Hematopoietic Stem Cell Transplantation (33 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Clayton A. Smith is often cited by papers focused on Acute Myeloid Leukemia Research (42 papers), Hematopoietic Stem Cell Transplantation (33 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Clayton A. Smith collaborates with scholars based in United States, Canada and United Kingdom. Clayton A. Smith's co-authors include Daniel A. Pollyea, Craig T. Jordan, Maura Gasparetto, Brett M. Stevens, Shanshan Pei, Jonathan A. Gutman, Robert W. Storms, O. Michael Colvin, Angelo D’Alessandro and Courtney L. Jones and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Clayton A. Smith

120 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

2018 481 citations Daniel A. Pollyea, Brett M. Stevens et al. Nature Medicine profile →
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

2018 388 citations Courtney L. Jones, Brett M. Stevens et al. profile →

Peers

Countries citing papers authored by Clayton A. Smith

Since Specialization

Citations

This map shows the geographic impact of Clayton A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clayton A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clayton A. Smith more than expected).

Fields of papers citing papers by Clayton A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clayton A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clayton A. Smith. The network helps show where Clayton A. Smith may publish in the future.

Co-authorship network of co-authors of Clayton A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Clayton A. Smith. A scholar is included among the top collaborators of Clayton A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clayton A. Smith. Clayton A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling 2025 ·Journal of the American Medical Informatics Association ·(unknown), David J. Albers, Jennifer Kwak, Clayton A. Smith, Tellen D. Bennett, Steven M. Bair	0
2	Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial 2023 ·Blood Advances ·Bradley M. Haverkos, Jasmine M. Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Dávila, (unknown), Ajay Major, Steven M. Bair, Jagar Jasem, Clayton A. Smith, Diana Abbott, Pierluigi Porcu	2
3	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy 2020 ·Clinical Cancer Research ·Zachary J. Walker, (unknown), (unknown), Brett M. Stevens, (unknown), (unknown), (unknown), Andrew Hammes, Clayton A. Smith, Craig T. Jordan, Tomer M. Mark, Peter A. Forsberg, Daniel W. Sherbenou	9
4	Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells 2020 ·Nature Cancer ·Brett M. Stevens, Courtney L. Jones, Daniel A. Pollyea, Rachel Culp‐Hill, Angelo D’Alessandro, Amanda Winters, Anna Krug, Diana Abbott, (unknown), Shanshan Pei, Haobin Ye, Austin E. Gillen, Michael W. Becker, Michael R. Savona, Clayton A. Smith, Craig T. Jordan	178
5	Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy 2019 ·Leukemia Research ·Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, Brett M. Stevens, Clayton A. Smith, Paul A. Seligman	18
6	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis 2019 ·Leukemia Research ·Brett M. Stevens, Amanda Winters, Jonathan A. Gutman, Aaron Fullerton, (unknown), (unknown), (unknown), Qi Wei, Taher Abbasi, Shireen Vali, (unknown), Leylah Drusbosky, Christopher R. Cogle, Andrew Hammes, Diana Abbott, Craig T. Jordan, Clayton A. Smith, Daniel A. Pollyea	4
7	Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia breakdown → 2018 ·Nature Medicine ·Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Rachel Culp‐Hill, Kent Riemondy, Austin E. Gillen, Jay R. Hesselberth, Diana Abbott, (unknown), Jonathan A. Gutman, Enkhtsetseg Purev, Clayton A. Smith, Craig T. Jordan	481
8	Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison 2018 ·Biology of Blood and Marrow Transplantation ·(unknown), Daniel A. Pollyea, Clayton A. Smith, Enkhtsetseg Purev, Manali Kamdar, Bradley M. Haverkos, Daniel W. Sherbenou, Rachel Rabinovitch, Andrew Hammes, Jonathan A. Gutman	6
9	Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1 2018 ·Blood ·Daniel A. Pollyea, Courtney L. Jones, Brett M. Stevens, Shanshan Pei, Angelo D’Alessandro, Rachel Culp‐Hill, Diana Abbott, Andrew Hammes, (unknown), Jonathan A. Gutman, Enkhtsetseg Purev, Clayton A. Smith, Craig T. Jordan	5
10	Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells 2016 ·Journal of Biological Chemistry ·Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Travis Nemkov, Brett M. Stevens, Biniam Adane, Nabilah Khan, Fred K. Hagen, Vinod Kumar Yadav, Subhajyoti De, John M. Ashton, Kirk C. Hansen, Jonathan A. Gutman, Daniel A. Pollyea, Peter A. Crooks, Clayton A. Smith, Craig T. Jordan	33
11	Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation 2016 ·Bone Marrow Transplantation ·Jonathan A. Gutman, Kelly Ross, Clayton A. Smith, Han Myint, Choon‐Ki Lee, Rachel B. Salit, Filippo Milano, Colleen Delaney, Dexiang Gao, Daniel A. Pollyea	37
12	Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice 2013 ·Cancer Chemotherapy and Pharmacology ·Robert A. Parise, Jan H. Beumer, (unknown), Lora H. Rigatti, (unknown), Maura Gasparetto, Clayton A. Smith, Julie L. Eiseman	6
13	Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential 2009 ·Blood ·David G. Kent, Michael R. Copley, Claudia Benz, Stefan Wöhrer, Brad Dykstra, Elaine Ma, (unknown), Zhao Yong-jun, Michelle B. Bowie, Yun Zhao, Maura Gasparetto, Allen Delaney, Clayton A. Smith, Marco A. Marra, Connie J. Eaves	251
14	Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy 2008 ·Blood ·Carolyn Owen, Cynthia L. Toze, (unknown), Donna L. Forrest, Clayton A. Smith, Jane Stevens, Shannon Jackson, Man‐Chiu Poon, Gary Sinclair, Brian Leber, Peter Johnson, (unknown), John A. Liu Yin, Michael J. Barnett, Tim Lister, Jude Fitzgibbon	168
15	Dispermic chimerism identified during HLA typing for stem cell transplantation 2008 ·Transfusion ·Nicole L. Draper, (unknown), Clayton A. Smith, Kaaron Benson	7
16	The Challenges of Targeting Chronic Myeloid Leukemia Stem Cells 2007 ·Clinical Lymphoma & Myeloma ·Xiaoyan Jiang, Clayton A. Smith, Allen Eaves, Connie J. Eaves	13
17	Maintenance of Proliferative Capacity and Retroviral Transduction Efficiency of Human Fetal CD38 ^– /CD34 ⁺⁺ Stem Cells 2006 ·Stem Cells and Development ·Marcus O. Muench, (unknown), Clayton A. Smith, David L. Suskind, Alicia Bárcena	3
18	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation 2005 ·Journal of Clinical Oncology ·Donna L. Forrest, Donna E. Hogge, Thomas J. Nevill, Stephen H. Nantel, Michael J. Barnett, John D. Shepherd, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith, Julye C. Lavoie, Kevin Song, Nicholas Voss, Randy D. Gascoyne, Joseph M. Connors	39
19	High-Efficiency Retroviral Transduction of Fetal Liver CD38–CD34++ Cells: Implications for in utero and ex utero Gene Therapy 2001 ·Fetal Diagnosis and Therapy ·(unknown), Alicia Bárcena, Clayton A. Smith, Michael R. Harrison, Marcus O. Muench	7
20	Retroviral Vector-Mediated Gene Transfer into Hematopoietic Cells: Prospects and Issues 1992 ·Journal of Hematotherapy ·Clayton A. Smith	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact